Therefore, one way to prevent HSC activation and reduce hepatic fibrosis is to inhibit activated HSCs by stopping the TGF-β/Smad3 signaling pathway, which is considered a potential therapeutic target (14-16). Here, SMAD3 is linked to Hepatic fibrosis.